CV Sciences director Charlie Cheever III acquires $20,307 in common stock
SELLAS Life Sciences Group, Inc. successfully completed its stock offering today. The company issued 13,269,231 shares of common stock at $13.00 per share, raising $172.5 million before accounting for underwriting fees and expenses. J.P. Morgan and TD Cowen served as lead book-running managers, with Mizuho acting as a co-managing underwriter.
Mizuho also served as a lead manager, alongside A.G.P./Alliance Global Partners and Maxim Group LLC. The offering was facilitated by a previously filed Form S-3 shelf registration statement with the Securities and Exchange Commission, which became effective upon its March 20, 2026 filing. SELLAS specializes in developing cancer therapies, with its primary product candidate, GPS, licensed from Memorial Sloan Kettering Cancer Center.
This drug targets the WT1 protein found in various tumors. Additionally, the company is advancing SLS009, a small molecule CDK9 inhibitor, for treating acute myeloid leukemia in patients with poor prognostic factors.
Rewritten by urgent.news; may contain errors — check the original.
This story
This is one outlet's version. Read the fullest account.